Literature DB >> 20003030

Donor hypo- and hypernatremia are predictors for increased 1-year mortality after cardiac transplantation.

Daniel Hoefer1, Elfriede Ruttmann-Ulmer, Jacqueline M Smits, Erwin Devries, Herwig Antretter, Guenther Laufer.   

Abstract

Donor hypernatremia is known to be associated with initial graft dysfunction in liver transplantation. Controversial data exist regarding the impact of sodium dysregulation on patient survival after heart transplantation (HTX). The aim of this study was to investigate the influence of donor sodium levels on survival in a large cohort of heart transplant recipients from the Eurotransplant registry. From 1997 to 2005, all consecutive adult HTX performed in the Eurotransplant region were included into this study (n = 4641 patients). Multivariate analysis was applied to investigate possible clinical predictors for 1-year post-transplant survival after cardiac transplantation (donor sodium levels, donor age, donor cause of death, recipient age, primary disease, urgency status, cold ischemia time). In multivariate analysis, recipients receiving a donor heart with serum sodium level lower than 130 mmol/l or higher than 170 mmol/l had a 1.25-fold higher risk for 1-year post-transplant mortality than patients with normal donor sodium ranges (P = 0.007). Other independent risk factors for impaired 1-year survival were recipient age, the indication for transplantation and the urgency status of the recipient. Our study demonstrates that hyponatremia as well as hypernatremia show a strong U-shaped correlation with poor survival after cardiac transplantation. Accurate donor management to avoid electrolyte disorder seems to be crucial for ensuring good quality of donor hearts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20003030     DOI: 10.1111/j.1432-2277.2009.01024.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

1.  Clinical Associations of Early Dysnatremias in Critically Ill Neonates and Infants Undergoing Cardiac Surgery.

Authors:  Jon Kaufman; Daniel Phadke; Suhong Tong; Jennifer Eshelman; Sarah Newman; Christopher Ruzas; Eduardo M da Cruz; Suzanne Osorio
Journal:  Pediatr Cardiol       Date:  2016-11-08       Impact factor: 1.655

Review 2.  A Systematic Review of Donor Serum Sodium Level and Its Impact on Transplant Recipients.

Authors:  J Basmaji; L Hornby; B Rochwerg; P Luke; I M Ball
Journal:  Int J Organ Transplant Med       Date:  2020

3.  [Evaluation of the potential organ donor with special regards to heart donation].

Authors:  Daniel Höfer; Arezu Aliabadi; Christian Ebner; Christoph Hörmann; Stephane Mahr; Regina Mascherbauer; Gerhard Pölzl; Albert Reiter; Andrä Wasler; Thomas Weber; Michael Zink; Andreas Zuckermann; Herwig Antretter
Journal:  Wien Klin Wochenschr       Date:  2010-07-16       Impact factor: 1.704

4.  Intracerebral bleeding in donors is associated with reduced short-term to midterm survival of heart transplant recipients.

Authors:  Daniel Oehler; Moritz Benjamin Immohr; Sophia Erbel-Khurtsidze; Hug Aubin; Raphael Romano Bruno; Hans Torulv Holst; Ralf Westenfeld; Patrick Horn; Malte Kelm; Igor Tudorache; Payam Akhyari; Artur Lichtenberg; Udo Boeken
Journal:  ESC Heart Fail       Date:  2022-05-04

5.  Outcome and Midterm Survival after Heart Transplantation Is Independent from Donor Length of Stay in the Intensive Care Unit.

Authors:  Daniel Oehler; Charlotte Böttger; Moritz Benjamin Immohr; Raphael Romano Bruno; Jafer Haschemi; Daniel Scheiber; Patrick Horn; Hug Aubin; Igor Tudorache; Ralf Westenfeld; Payam Akhyari; Malte Kelm; Artur Lichtenberg; Udo Boeken
Journal:  Life (Basel)       Date:  2022-07-14

6.  Donor Hypernatremia is Not Related with the Duration of Postoperative Mechanical Ventilation, Primary Graft Dysfunction, or Long-Term Outcome Following Lung Transplantation.

Authors:  Annemieke Oude Lansink-Hartgring; Lara Hessels; Adrianus J de Vries; Wim van der Bij; Erik A M Verschuuren; Michiel E Erasmus; Maarten W N Nijsten
Journal:  Ann Transplant       Date:  2018-07-24       Impact factor: 1.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.